Smithkline Beckman Corp said its
genetically engineered hepatitis B vaccine has received
regulatory approval for marketing in Switzerland and
Luxembourg.
    The vaccine, called Engerix-B, has been approved in several
other countries, including Belgium and Hong Kong.
    Smithkline said it is currently considering marketing
avenues in the United States.
    Merck and Co &lt;MRK> also has a genetically engineered
vaccine being marketed in several foreign markets, according to
industry sources.
 Reuter
&#3;